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Edited by Bernd HelmsAbstract Barth syndrome is an X-linked recessive disease
caused by mutations in the tafazzin gene. Patients have reduced
concentration and altered composition of cardiolipin, the speciﬁc
mitochondrial phospholipid, and they have variable clinical ﬁnd-
ings, often including heart failure, myopathy, neutropenia, and
growth retardation. This article provides an overview of the
molecular basis of Barth syndrome. It is argued that tafazzin,
a phospholipid acyltransferase, is involved in acyl-speciﬁc remod-
eling of cardiolipin, which promotes structural uniformity and
molecular symmetry among the cardiolipin molecular species.
Inhibition of this pathway leads to changes in mitochondrial
architecture and function.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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About a quarter of a century ago, Peter Barth and his col-
leagues described a Dutch family with a three-generation his-
tory of infantile cardiomyopathy, in which abnormal
mitochondria were implicated [1,2]. The disorder showed an
X-linked recessive inheritance pattern and was similar in many
aspects to a mitochondrial cardiomyopathy that was found
two years earlier in another pedigree by Neustein et al. [3].
Since then, more cases have been identiﬁed in regions far apart,
such as Australia [4], Europe [5], Japan [6], and North America
[7], but the incidence is still unknown due to the lack of suit-
able demographic data.
The classical presentation of this cardiomyopathy, which to-
day is known as Barth syndrome (MIM 302060), also includes
skeletal muscle weakness, neutropenia, and growth retardation
[2,7]. Furthermore, two metabolic abnormalities are typically
present, namely elevated urinary excretion of 3-methylgluta-
conic acid and hypocholesterolemia [7]. A mild cognitive phe-
notype has been described as well [8]. However, there is
considerable variability in the age of onset, the expression of
symptoms, and the progression of the disease. The majority*Corresponding author. Address: Department of Anesthesiology, New
York University School of Medicine, 550 First Avenue, New York,
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doi:10.1016/j.febslet.2006.07.022of patients registered with the Barth Syndrome Foundation
(www.barthsyndrome.org) are children, although this is likely
to change as the improved overall care reduces infant and
childhood mortality.
The current patient population covers a wide range of indi-
viduals from those who have severe debilitating disease to
those who are nearly asymptomatic. The characteristic symp-
toms of Barth syndrome (cardiomyopathy, skeletal myopathy,
neutropenia, growth retardation) are not consistently present
in every patient and the clinical situation may change as
patients grow older. Nevertheless, the most serious ﬁnding is
usually cardiomyopathy, presenting either as biventricular
dilatation or as left-ventricular non-compaction [9]. Sudden
episodes of cardiac deterioration are common and are often
followed by unexplained remissions. This obscure clinical pat-
tern has led many to refer to Barth syndrome as a ‘‘mystery
disease’’. It has also made it challenging for physicians to
establish the correct diagnosis in Barth patients.
About 10 years after the ﬁrst description of Barth syndrome,
the locus for the disease was mapped to the distal portion of
Xq28 [4,10] and mutations were eventually identiﬁed in G4.5
[11], a gene that is ubiquitously expressed in human tissues
[12]. This gene has the potential to form several proteins be-
cause 3 of its 11 exons may undergo diﬀerential splicing [11].
Since the G4.5 protein products have been named tafazzins,
in reference to a comic Italian television character [11], G4.5
is now commonly referred to as the tafazzin gene. Many diﬀer-
ent mutations have been identiﬁed in this gene over the past
decade, yet no clear correlation has emerged between the geno-
types and the various phenotypes that patients present with
[6,9,13–15].
Although the nucleotide sequence and transcriptional orga-
nization of the tafazzin gene suggest that it may express up to
twelve diﬀerent mRNA species [11], only four species have
actually been found in human tissues [16,17]. These include
the full-length mRNA as well as three shorter mRNAs in
which either exon 5, or exon 7, or both exon 5 and exon 7,
are missing. The corresponding proteins range from 28.5 to
33.5 kDa in size (248–292 amino acids).
Homologs of human tafazzin are present in the genomes of
many diverse eukaryotes, such as yeast, roundworm, fruit ﬂy,
and mammals to name a few. These tafazzins form a subgroup
within a large superfamily of proteins with known and putative
acyltransferase function [18]. Since the known members of this
superfamily use lysophospholipid substrates, it has been postu-
lated that tafazzins are acyltransferases involved in phospho-
lipid metabolism.blished by Elsevier B.V. All rights reserved.
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The ﬁrst evidence for a role of tafazzin in phospholipid
metabolism was provided by Peter Vreken and colleagues
who showed that ﬁbroblast cultures from Barth patients con-
tain less cardiolipin than control cultures [19]. Cardiolipin is
a dimeric phospholipid (Fig. 1) that is speciﬁcally localized
in mitochondria [20]. Since the rate of cardiolipin synthesis
was not aﬀected in Barth ﬁbroblasts, the authors suspected
that the low concentration of cardiolipin was caused by in-
creased degradation [19]. Under normal conditions, cardiolipin
is degraded to monolysocardiolipin and then converted back
into cardiolipin in order to exchange its fatty acids [21]. In
Barth ﬁbroblasts, the deacylation–reacylation cycle seemed
to be impaired because the incorporation of linoleic acid into
cardiolipin was reduced [19]. This observation in conjunction
with the low cardiolipin level suggested a decline in the rate
of reacylation relative to the rate of deacylation. Several years
later, the idea of insuﬃcient reacylation was corroborated
when monolysocardiolipin was shown to accumulate in Barth
patients [22] and in tafazzin-deﬁcient yeast [23].
Involvement of acyl remodeling was also inferred from the
analysis of cardiolipin species in Barth patients [24]. Interest-
ingly, only a singlemolecular species, namely tetralinoleoyl–car-
diolipin, was missing in the patients, whereas other cardiolipins
were either unaﬀected or even increased. Tetralinoleoyl–cardio-
lipin is the dominant species in heart and skeletal muscle, where
the defect was originally discovered [24]. However, tetra-
linoleoyl–cardiolipin was also deﬁcient in platelets [24–26],
ﬁbroblasts [27], and granulocytes [28]. Because platelet samples
are readily available from patients, it was possible to investigate
the speciﬁcity of the cardiolipin defect for Barth syndrome and
to explore its potential diagnostic utility [25]. Tetralinoleoyl–
cardiolipin deﬁciencywas shown to be a speciﬁcmarker of Barth
syndrome, distinguishing this disease from related cardiomyop-
athies and skeletal muscle disorders. As a result, the platelet testFig. 1. Structure of cardiolipin. The molecule consists of two sn-
glycero-3-phosphate moieties linked by a glycerol group. Four acyl
groups (X1, X2, Y1, Y2) are attached to the glycerophosphates. Both
glycerophosphates carry obligate chiral centers in R conformation. The
central glycerol carries a prochiral center (if X1 = Y1 and X2 = Y2) or a
true chiral center (if X1 „ Y1 or X2 „ Y2). As a result, the two
glycerophosphates occupy diﬀerent stereochemical positions [36].for cardiolipin is now being used in the work-up of patients in
whom Barth syndrome is considered as a diﬀerential diagnosis
[25,26].
Besides the change in cardiolipin composition, there is a
consistent decrease in the total concentration of cardiolipin
not only in heart [22,24,25] and skeletal muscle [24,25], but
also in platelets [24–26], granulocytes [28], lymphocytes [22],
cultured lymphoblasts [22,25] and cultured ﬁbroblasts
[19,25,27]. In contrast, the concentration of other phospholip-
ids does not seem to change signiﬁcantly [19,25]; but this does
not imply that the eﬀects of Barth syndrome are strictly con-
ﬁned to cardiolipin. For instance, in heart biopsies from Barth
patients, the molecular compositions of phosphatidylcholine
and phosphatidylethanolamine are altered due to an increase
in linoleoyl-containing species, in particular 1-palmitoyl-2-lin-
oleoyl-phosphatidylcholine and 1-stearoyl-2-linoleoyl-phos-
phatidylethanolamine, at the expense of the corresponding
arachidonoyl-containing species [22,25]. The molecular com-
position of phosphatidylcholine is also altered in lymphoblasts
[29]. These changes, albeit small in comparison to cardiolipin,
may nevertheless be relevant and they may in fact be related to
the metabolism of cardiolipin, which will be discussed in Sec-
tion 4.3. Abnormal molecular species of cardiolipin
The speciﬁc lack of tetralinoleoyl–cardiolipin created the
idea that Barth syndrome is simply caused by inadequate
incorporation of linoleic acid; thus supplementation with lino-
leic acid was proposed as a treatment [30]. However, it soon
became clear that tafazzin mutations also alter the cardiolipin
composition of lymphoblasts, in which tetralinoleoyl–cardio-
lipin is not present [31]. Likewise, the molecular pattern of car-
diolipin is aﬀected by deletion of the tafazzin gene in yeast,
although linoleic acid is not present in yeast cardiolipin
[23,32]. Therefore, a diﬀerent paradigm is needed to explain
why tafazzin mutations change the molecular composition of
cardiolipin.
To recognize the essential nature of the tafazzin eﬀect, it is
informative to compare the cardiolipin composition of tafazzin
mutants in humans [24,31], yeast [23,32], and fruit ﬂies [33]. In
all three examples, mutations cause a diversiﬁcation of the car-
diolipin pattern, i.e. the pattern changes from one that is dom-
inated by a few major molecular species to one that contains
multiple minor species. It appears that structural uniformity,
or the selection of a limited number of molecular species, is
an important feature of normal cardiolipin. Indeed, structural
uniformity was found among cardiolipins from diverse eukary-
otic organisms despite their diﬀerences in fatty acid composi-
tion [34]. Only one or two kinds of fatty acids are usually
selected for the assembly of cardiolipins. For instance, in many
mammalian tissues, cardiolipin has a strong preference for lin-
oleic acid [24], in bivalves it is docosahexaenoic acid [35], and
in Drosophila it is both linoleic and palmitoleic acid [34].
What is the function of the selective incorporation of fatty
acids into cardiolipin and why may the absence of such selec-
tivity be a disadvantage? While a convincing answer to this
question has yet to be found, we would like to discuss the
structural implications of random cardiolipin acylation, which
seems to take place in patients with Barth syndrome. As shown
in Fig. 1, each acyl residue of cardiolipin is attached to a ster-
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ester site is related to the prochirality of the central glycerol,
which makes one glycerophosphate pro-S (1 0-linked) and the
other one pro-R (3 0-linked) [36]. As a result, there are four dis-
tinguishable sites, namely sn-1 0-(1-glycerol), sn-1 0-(2-glycerol),
sn-3 0-(1-glycerol), and sn-3 0-(2-glycerol). This implies that N4
positional permutations are possible in a cardiolipin with N
types of fatty acids. For example, 625 cardiolipin species could
occur in yeast that contains ﬁve fatty acids, and 38416 cardio-
lipin species could occur in humans with fourteen fatty acids.
Thus, Barth patients contain a nearly inﬁnite variety of cardi-
olipin species generated by random acyl substitution. In con-
trast, normal individuals and normal eukaryotic organisms
contain only a limited number of cardiolipin species due to
the strong selection of speciﬁc fatty acids.
We have identiﬁed three diﬀerent scenarios for the assembly
of cardiolipin species, which are based on the selective incorpo-
ration of one, two, or three types of fatty acids (Fig. 2) [34]. If
one fatty acid is selected, such as in many mammalian tissues,
only a single molecular species becomes the dominant compo-
nent of cardiolipin (Fig. 2A). If two fatty acids are selected,
such as in fruit ﬂies, 16 molecular species emerge (Fig. 2B).
If three fatty acids are selected, such as in the sea urchin A.
punctulata, one would expect a total of 81 molecular species.
However, positional speciﬁcity among the three fatty acids lim-
its the number of molecular species to four (Fig. 2C). Fatty
acid speciﬁcity of cardiolipin not only creates structural unifor-
mity, it also increases the degree of molecular symmetry, i.e.
the formation of molecular species with identical 1,2-diacyl-
glycerol moieties [34]. When the process of fatty acid selection
is impaired, like in patients with Barth syndrome, mostly
asymmetric cardiolipin species are formed, in which the pro-
chiral carbon atom of the central glycerol group becomes aFig. 2. Molecular species of cardiolipin in diﬀerent organisms. Each
species is presented as a drawing, in which color-coded acyl groups are
attached to the following carbon atoms (from left to right): sn-1 0-(1-
glycerol), sn-1 0-(2-glycerol), sn-3 0-(2-glycerol), and sn-3 0-(1-glycerol).
(A) Cardiolipin from human heart. (B) Cardiolipin from D. melano-
gaster. (C) Cardiolipin from A. punctulata. See Ref. [34] for experi-
mental data. Color code: blue, palmitoelic acid (16:1); yellow, oleic
acid (18:1); red, linoleic acid (18:2); green, docosadienoic acid (20:2);
brown, docosapentaenoic acid (20:5).true chiral center. The signiﬁcance of cardiolipin chirality has
not been studied, but several ideas about the role of molecular
symmetry in cardiolipin have been discussed in a previous arti-
cle [34].4. The role of tafazzin
What is the mechanism by which cardiolipin acquires a spe-
ciﬁc fatty acid proﬁle? Like many other phospholipids, cardio-
lipin undergoes remodeling of its acyl moieties after de novo
formation. This remodeling consists of a deacylation–reacyla-
tion cycle [21], similar to the classical Lands pathway [37].
However, in contrast to the Lands pathway that uses acyl-
coenzyme A as substrate, cardiolipin remodeling was shown
to use acyl groups from other phospholipids [31]. In rat liver
mitochondria, this transacylation is highly speciﬁc for linoleoyl
residues, which supports the idea that transacylation is the crit-
ical step in shaping the fatty acid proﬁle of cardiolipin. Deac-
ylation of cardiolipin, which is also essential for remodeling,
appears to have no acyl speciﬁcity [31].
The enzymes involved in cardiolipin remodeling have re-
mained obscure for many years. Two acyl-CoA dependent en-
zymes have been identiﬁed, which are capable to reacylate
monolysocardiolipin in vitro, but they do not have any strong
acyl speciﬁcity [38,39]. Tafazzin was implicated in cardiolipin
remodeling because mutations in the tafazzin gene cause an in-
crease of monolysocardiolipin, a decrease of cardiolipin, and a
change of the cardiolipin composition [22–25]. These eﬀects
were reversible by tafazzin expression in the Dtaz yeast strain
[32], strongly suggesting that tafazzin catalyzes the reacylation
of monolysocardiolipin. In light of the proposed transacyla-
tion mechanism of cardiolipin remodeling [31], the question
arises whether tafazzin is in fact a transacylase.
Tafazzin belongs to a protein superfamily, of which several
members transfer activated fatty acids to glycero-3-phosphate
either from acyl-coenzyme A or from acyl–acyl–carrier pro-
tein, another phosphopantetheine based coenzyme [18]. While
these activities are consistent with an acyltransferase function,
they do not speciﬁcally suggest a transacylation mechanism.
However, tafazzins form a distinct subgroup within the super-
family, so their speciﬁc catalytic function can not be inferred
from alignment analysis alone. There are now several lines of
evidence to suggest that tafazzin has indeed transacylase activ-
ity. First of all, tafazzin deﬁciency is associated with a signiﬁ-
cant decrease of the phospholipid transacylation rate in
lymphoblast mitochondria [31]. Second, yeast tafazzin was
shown to catalyze reacylation of lysophosphatidylcholine in
the absence of acyl-coenzyme A [40], a reaction for which
transacylation is a likely mechanism. Third, we recently ex-
pressed Drosophila tafazzin in Sf9 insect cells and showed that
it can exchange fatty acids between cardiolipin and phosphati-
dylcholine in a reversible, acyl-speciﬁc manner (unpublished
data).
Finally, the eﬀect of tafazzin mutations on the species pat-
tern of phosphatidylcholine is consistent with the idea that
tafazzin transfers speciﬁc fatty acids from phosphatidylcholine
to cardiolipin. In patients with Barth syndrome, the same fatty
acids that fail to accumulate in cardiolipin, do accumulate in
phosphatidylcholine [25,29], suggesting that acyl groups nor-
mally ﬂow from phosphatidylcholine to cardiolipin. Fig. 3
illustrates the cardiolipin–phosphatidylcholine transacylation
M. Schlame, M. Ren / FEBS Letters 580 (2006) 5450–5455 5453pathway. It is important to note that transacylations are near-
equilibrium reactions that can not be the underlying mecha-
nism for unidirectional fatty acid transfer from one phospho-
lipid to another, unless they are coupled to an irreversible
reaction. The driving force of fatty acid transfer may be the
hydrolysis of acyl-coenzyme A, if the cardiolipin–phosphati-
dylcholine transacylation is coupled on one end to the hydro-
lysis of cardiolipin and on the other end to the reacylation of
lysophosphatidylcholine (Fig. 3).5. Involvement of mitochondria
Barth syndrome was originally described as a mitochondrial
disease because tissue biopsies contained mitochondria with
abnormal ultrastructure and diminished respiratory function
[2]. The involvement of mitochondria in Barth syndrome seems
plausible from our current prospective because tafazzin, the
mutated enzyme, is localized in mitochondria [40,41] and so
is cardiolipin, its primary metabolic target [22–25]. Barth syn-
drome seems to be unique among mitochondrial diseases since
cardiolipin deﬁciency is not commonly present in patients with
MELAS, Leigh syndrome, cytochrome oxidase deﬁciency, and
mitochondrial DNA deletions [42].
Cardiolipin is mostly found in the inner mitochondrial mem-
brane, where it interacts with many of the proteins involved in
oxidative phosphorylation [20]. The unusually strong binding
of cardiolipin to a number of diﬀerent proteins, makes it an
essential factor for the tertiary and quarternary protein struc-
ture and, by extension, the supramolecular organization of the
crista membrane. For instance, cardiolipin occupies critical
positions in the crystal structure of respiratory complex III
[43] and the ADP–ATP carrier [44]. Cardiolipin also promotes
the formation of supercomplexes from individual components
of the respiratory chain [45,46]. Not surprisingly, the super-
complex equilibrium is aﬀected by disruption of the tafazzin
gene, so in Dtaz yeast mitochondria, respiratory complexes
tend to exist in the dissociated state [47]. Thus, Barth syn-
drome may potentially interfere with assembly and stability
of the respiratory chain, although the role of cardiolipin in
mitochondrial biogenesis is not very well established. Cardio-
lipin is synthesized at the matrix side of the inner membrane
in rat liver mitochondria [48]. In contrast, tafazzin is localized
in the outer membrane of yeast mitochondria with its predicted
catalytic domain exposed to the intermembrane space [47].
This suggests that de novo formation and remodeling of cardi-
olipin may occur at diﬀerent sites and it raises questions as to
where cardiolipin is incorporated into the respiratory com-
plexes and how protein import is coordinated with cardiolipin
formation and remodeling.CoA
Acyl-CoA
PC
LPCCL
MLCL
H2O
FA
1 32
Fig. 3. Proposed mechanism of cardiolipin remodeling. (1) CL
deacylation; (2) PC-CL transacylation (tafazzin reaction); (3) LPC
reacylation. This pathway may reshuﬄe fatty acids due to the acyl
speciﬁcity of the individual reactions. The net reaction of the pathway
is: Acyl-CoA + H2Oﬁ FA + CoA. Abbreviations. CL, cardiolipin;
CoA, coenzyme A; FA, fatty acid; LPC, lysophosphatidylcholine;
MLCL, monolysocardiolipin; PC, phosphatidylcholine.Studies on Barth syndrome may provide unique insights into
the role of cardiolipin in crista membrane assembly. Tissue
biopsies from Barth patients contain mitochondria with bun-
dles of stacked and compacted cristae that seem to be largely
disconnected from the inner boundary membrane [49]. We
found related abnormalities in ﬂight muscle mitochondria of
Drosophila with tafazzin mutation [33]. Electron tomography
of abnormal cristae in Barth lymphoblasts showed a collapse
of the intracrista space due to adhesion of the two opposing
membranes (unpublished data). These structural changes sug-
gest gross abnormalities in the assembly process, which will be
dissected in future studies. Collapse of the intracrista space
is probably incompatible with oxidative phosphorylation
because this space is required for substrate diﬀusion and it
supplies the protons for the electrochemical gradient.
Oxidative phosphorylation has been studied in lymphoblasts
from Barth patients [29] and in tafazzin-deﬁcient yeast [41].
There was a mild decrease in coupling eﬃciency, as shown
by a decrease in state-3 respiration, an increase in state-4 res-
piration, and a decrease in the mitochondrial membrane
potential. However, the overall ability to produce ATP was
preserved, perhaps because of mitochondrial proliferation,
which may compensate for the loss of mitochondrial function
[29].6. Pathogenesis of Barth syndrome
The current concept of Barth syndrome places cardiolipin at
the center of the molecular pathogenesis. Cardiolipin deﬁ-
ciency is a plausible cause of mitochondrial dysfunction, which
in turn may be the underlying mechanism for myopathy and
heart failure. This idea is supported by our recent work in Dro-
sophila, where tafazzin deletion leads to abnormal cardiolipin,
abnormal mitochondria, and motor weakness of the indirect
ﬂight muscles [33]. However, many questions with regard to
the pathogenesis of Barth syndrome, remain to be answered.
For instance, the clinical presentation of Barth syndrome is
too sophisticated to be accounted for by a mere breakdown of
energy metabolism. In several ways, Barth syndrome shows the
pattern of a developmental disease that interferes with embryo-
genesis and the maturation of organ systems. This is speciﬁ-
cally suggested by left-ventricular non-compaction in some
newborns with Barth syndrome, a phenotype that is the result
of impaired cardiac morphogenesis [6,9]. The variability in
clinical presentation of Barth patients is also consistent with
the idea that the syndrome is modulated by embryogenetic fac-
tors. The identiﬁcation of these factors is one of the future
challenges in Barth syndrome research.
While cardiolipin has been implicated in the etiology of
Barth syndrome, it is not known whether it is the reduced con-
centration of cardiolipin or the altered composition of cardio-
lipin that is more important for the pathogenesis.
Mitochondrial functions, such as respiration and osmotic sta-
bility, correlated with the cardiolipin content in yeast deletion
mutants of tafazzin and cardiolipin synthase [41]. However,
the yeast model has its own limitations with respect to the tis-
sue-speciﬁc aspects of Barth syndrome. Interestingly, the cardi-
olipin concentration was almost normal in two cardiac
biopsies from Barth patients with severe cardiomyopathy
[25]. The same patients had drastic alterations in the pattern
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cardiolipin rather than its concentration that plays a role in
the pathomechanism. Nevertheless, severe reductions in the
cardiolipin content are likely to have consequences for mito-
chondrial function.
The cardiolipin defect may aﬀect various cellular functions
that involve mitochondria, such as oxidative phosphorylation
or the initiation of apoptosis by cytochrome c release. Studies
have demonstrated a loss of energy coupling eﬃciency in cellu-
lar models of Barth syndrome [29,41], but the eﬀects are subtle
and it is not clear whether insuﬃcient ATP supply is a patho-
genetic factor in Barth syndrome. It is conceivable though,
that oxidative phosphorylation becomes exhausted in tissues
like heart or skeletal muscle during periods of high energy de-
mand. Apoptosis has also been studied in neutrophils [28] and
lymphoblasts [22] of Barth patients, but no diﬀerence was
found to the controls.
Furthermore, mitochondrial biogenesis may be aﬀected in
Barth syndrome. It is intriguing that some genetic diseases,
in which mitochondrial biogenesis is likely involved, may pres-
ent with Barth syndrome-like clinical features. This is true for
a mutation in a putative component of the mitochondrial pro-
tein import system [50] and for a MELAS-type mutation of the
mitochondrial DNA [51]. Barth syndrome may alter the
growth of mitochondria and their intracellular distribution be-
cause the disease is expressed in tissues in which the mitochon-
drial network shows a high level of structural organization. In
heart and skeletal muscle, mitochondria are arranged around
the contractile apparatus in a crystal-like pattern [52], the for-
mation of which may require an intact cardiolipin metabolism.
Finally, one has to consider the possibility that extramito-
chondrial functions are involved in the pathogenesis of Barth
syndrome. Since the tafazzin gene produces several transcripts
[16,17], they may be targeted to diﬀerent intracellular compart-
ments and they may be involved in more than one pathway. As
of yet, no evidence exists for this scenario, but the presence of
multiple tafazzin mRNA’s requires an explanation.
In conclusion, Barth syndrome is a mitochondrial disorder
caused by an inborn error of phospholipid metabolism. Tafaz-
zin deﬁciency inhibits speciﬁcally the acyl remodeling of cardi-
olipin. As a result, mitochondria contain reduced levels of
cardiolipin and the remaining cardiolipin lacks its characteris-
tic acyl pattern. The exact consequences for mitochondrial
function remain to be established, but they may include deﬁ-
ciencies in mitochondrial energy coupling and/or in mitochon-
drial biogenesis. Mitochondrial abnormalities in Barth
syndrome compromise the development and function of cer-
tain tissues, such as muscle and heart, in which high energy
turnover requires a strict structural organization of mitochon-
dria both in terms of their morphology and their intracellular
distribution.
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